WO2006105344A3 - Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders - Google Patents

Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders Download PDF

Info

Publication number
WO2006105344A3
WO2006105344A3 PCT/US2006/011764 US2006011764W WO2006105344A3 WO 2006105344 A3 WO2006105344 A3 WO 2006105344A3 US 2006011764 W US2006011764 W US 2006011764W WO 2006105344 A3 WO2006105344 A3 WO 2006105344A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
necrosis factor
tumor necrosis
associated disorders
lowering
Prior art date
Application number
PCT/US2006/011764
Other languages
French (fr)
Other versions
WO2006105344A2 (en
Inventor
Haim Burstein
William V Giannobile
Original Assignee
Targeted Genetics Corp
Haim Burstein
William V Giannobile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006230419A priority Critical patent/AU2006230419A1/en
Application filed by Targeted Genetics Corp, Haim Burstein, William V Giannobile filed Critical Targeted Genetics Corp
Priority to CA002603325A priority patent/CA2603325A1/en
Priority to JP2008504394A priority patent/JP2008536826A/en
Priority to EP06740114A priority patent/EP1871799A2/en
Publication of WO2006105344A2 publication Critical patent/WO2006105344A2/en
Publication of WO2006105344A3 publication Critical patent/WO2006105344A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)

Abstract

The present invention provides methods of using recombinant adeno-associated virus (rAAV) vectors encoding a tumor necrosis factor (TNF) antagonist for treatment of TNF-associated disorders or conditions such as bone loss, impairment of wound healing or bone healing, and oral buccal diseases.
PCT/US2006/011764 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders WO2006105344A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006230419A AU2006230419A1 (en) 2005-03-31 2006-03-30 Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
CA002603325A CA2603325A1 (en) 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
JP2008504394A JP2008536826A (en) 2005-03-31 2006-03-31 Methods for reducing levels of tumor necrosis factor (TNF) in TNF-related disorders
EP06740114A EP1871799A2 (en) 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66738805P 2005-03-31 2005-03-31
US60/667,388 2005-03-31

Publications (2)

Publication Number Publication Date
WO2006105344A2 WO2006105344A2 (en) 2006-10-05
WO2006105344A3 true WO2006105344A3 (en) 2007-01-11

Family

ID=37054152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011764 WO2006105344A2 (en) 2005-03-31 2006-03-31 Methods for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders

Country Status (5)

Country Link
EP (1) EP1871799A2 (en)
JP (1) JP2008536826A (en)
AU (1) AU2006230419A1 (en)
CA (1) CA2603325A1 (en)
WO (1) WO2006105344A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623978A1 (en) 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN104159916A (en) 2012-02-22 2014-11-19 Nvip私人有限公司 Tumour necrosis factor receptor fusion proteins and methods of using the same
AU2021369833A1 (en) * 2020-10-29 2023-06-08 Regenxbio Inc. Vectorized tnf-alpha antagonists for ocular indications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO2000073481A1 (en) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
WO2003014309A2 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO2000073481A1 (en) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
WO2003014309A2 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DELIMA A J ET AL: "Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis.", JOURNAL OF CLINICAL PERIODONTOLOGY. MAR 2001, vol. 28, no. 3, March 2001 (2001-03-01), pages 233 - 240, XP002404328, ISSN: 0303-6979 *
TABA ET AL: "677. Gene Delivery of TNFR:Fc by Adeno-Associated Virus Vector Blocks Progression of Periodontitis", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 11, 15 August 2005 (2005-08-15), pages 262, XP005016016, ISSN: 1525-0016 *

Also Published As

Publication number Publication date
AU2006230419A1 (en) 2006-10-05
CA2603325A1 (en) 2006-10-05
JP2008536826A (en) 2008-09-11
EP1871799A2 (en) 2008-01-02
WO2006105344A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
EP1865967A4 (en) Compounds, compositions and methods for the treatment of viral infections and other medical disorders
ATE407214T1 (en) METHODS AND COMPOSITIONS FOR REDUCING TUMOR NECROSIS FACTOR (TNF) LEVELS IN TNF-ASSOCIATED DISEASES
EP1622589A4 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2008036502A3 (en) Artificial spinal disc
EP2319925A3 (en) Therapeutic uses of inhibitors of RTP801
WO2003037890A3 (en) Piperidines
EP1578988A4 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
HK1098383A1 (en) Compositions and methods for treating coagulation related disorders
EP1583821A4 (en) Methods and compositions for treating urological disorders using 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 76
EP1771188A4 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
EP1861126A4 (en) Treatment of protein degradation disorders
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
WO2005048935A3 (en) Methods of modulating immunity
DE602005021970D1 (en) USE OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN BY BONE CANCER, CHEMOTHERAPY AND NUCLEOSIDE-RELATED PAIN
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2006088925A3 (en) Use of il17-f in diagnosis and therapy of airway inflammation
EP1814535A4 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
EP1686986A4 (en) Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2006109044A3 (en) Selective modulation of tumour necrosis factor receptors in therapy
WO2009015063A3 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2005092062A3 (en) Compounds for neurodegenerative disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006230419

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2603325

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008504394

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006740114

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006230419

Country of ref document: AU

Date of ref document: 20060330

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06740114

Country of ref document: EP

Kind code of ref document: A2